Based on the Stoke Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Stoke Therapeutics Inc is USD 25.40 over the next 12 months. Stoke Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Stoke Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Stoke Therapeutics Inc’s stock price was USD 8.33. Stoke Therapeutics Inc’s stock price has changed by -22.00% over the past week, -15.00% over the past month and +55.41% over the last year.
No recent analyst target price found for Stoke Therapeutics Inc
No recent average analyst rating found for Stoke Therapeutics Inc
Company Overview Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read Less
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucle...Read More
Frequently Asked Questions About Stoke Therapeutics Inc (STOK) Stock
Based on ratings from 5 analysts Stoke Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on STOK's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STOK is USD 25.40 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 18.
STOK stock's Price/Earning ratio is 21.65.
Our analysis grades STOK stock's Price / Earning ratio at F. This means that STOK stock's Price/Earning ratio is above 72% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STOK may be a overvalued for its sector.
The last closing price of STOK's stock was USD 8.33.
The most recent market capitalization for STOK is USD 0.60B.
Based on targets from 5 analysts, the average taret price for STOK is projected at USD 25.40 over the next 12 months.
This means that STOK's stock price may go up by +204.92% over the next 12 months.
We can't find any ETFs which contains Stoke Therapeutics Inc's stock.
As per our most recent records Stoke Therapeutics Inc has 110 Employees.
Stoke Therapeutics Inc's registered address is 45 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Stoke Therapeutics Inc's website at https://www.stoketherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Stoke Therapeutics Inc (STOK) Stock
Based on ratings from 5 analysts Stoke Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on STOK's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STOK is USD 25.40 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 18.
STOK stock's Price/Earning ratio is 21.65.
Our analysis grades STOK stock's Price / Earning ratio at F. This means that STOK stock's Price/Earning ratio is above 72% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STOK may be a overvalued for its sector.
The last closing price of STOK's stock was USD 8.33.
The most recent market capitalization for STOK is USD 0.60B.
Based on targets from 5 analysts, the average taret price for STOK is projected at USD 25.40 over the next 12 months.
This means that STOK's stock price may go up by +204.92% over the next 12 months.
We can't find any ETFs which contains Stoke Therapeutics Inc's stock.
As per our most recent records Stoke Therapeutics Inc has 110 Employees.
Stoke Therapeutics Inc's registered address is 45 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Stoke Therapeutics Inc's website at https://www.stoketherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STOK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
